Dr. Chin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Dna Way
# 454b
South San Francisco, CA 94080
Education & Training
University of WashingtonResidency, Neurology, 2000 - 2003
Geisel School of Medicine at DartmouthClass of 1999
Certifications & Licensure
CA State Medical License 2003 - 2015
Publications & Presentations
PubMed
- 1133 citationsOcrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.Stephen L. Hauser, Amit Bar-Or, Giancarlo Comi, Gavin Giovannoni, Hans Peter Hartung
The New England Journal of Medicine. 2017-01-19 - 1121 citationsOcrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalban, Stephen L. Hauser, Ludwig Kappos, Douglas L. Arnold, Amit Bar-Or
The New England Journal of Medicine. 2017-01-19 - 27 citationsOnset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis.Ludwig Kappos, Ernst-Wilhelm Radue, Peter Chin, Shannon Ritter, Davorka Tomic
Journal of Neurology. 2016-02-01
Press Mentions
FDA Approves First Drug to Treat Two Forms of MSMarch 29th, 2017
After 40 Years, First Drug for MS Wins FDA ApprovalMarch 28th, 2017
Full Transcript of Interview with Genentech’s Medical Director, Peter Chin, on OcrevusFebruary 28th, 2017- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
